Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Avadel Pharmaceuticals PLC
Total Equity
Avadel Pharmaceuticals PLC
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Total Equity
$98.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-11%
|
CAGR 10-Years
16%
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Total Equity
$4.4B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-8%
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Total Equity
$4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
3%
|
CAGR 10-Years
10%
|
|
|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
Total Equity
-$7.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Total Equity
€498.3m
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
2%
|
|
|
Ovoca Bio PLC
LSE:OVB
|
Total Equity
€2.1m
|
CAGR 3-Years
-46%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-21%
|
|
Avadel Pharmaceuticals PLC
Glance View
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 66 full-time employees. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.
See Also
What is Avadel Pharmaceuticals PLC's Total Equity?
Total Equity
98.2m
USD
Based on the financial report for Sep 30, 2025, Avadel Pharmaceuticals PLC's Total Equity amounts to 98.2m USD.
What is Avadel Pharmaceuticals PLC's Total Equity growth rate?
Total Equity CAGR 10Y
16%
Over the last year, the Total Equity growth was 32%.
